Camurus’ octreotide SC depot (CAM2029) achieves superior treatment response compared to placebo in Phase 3 acromegaly trial
· Primary and key secondary endpoints met for once monthly octreotide SC depot · Data show improvement in quality of life versus standard of care at baseline · Well tolerated safety profile with no new or unexpected findings · Company to host a conference call today at 1:30 pm CET Lund, Sweden — 20 June 2023 — Camurus (NASDAQ STO: CAMX) today announced positive topline results from a 24-week Phase 3, randomized, double-blind, placebo-controlled trial, ACROINNOVA 1, evaluating the efficacy and safety of the company’s octreotide